Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=10 Treatment

The Effects of Light Therapy on Circadian Rhythms, Sleep, and Mood in Postpartum Depression

Depression, Postpartum

Bottom Line

View on ClinicalTrials.gov: NCT02769858 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Change From Baseline Score of the Hamilton Depression Rating Scale-Seasonal Affective Version (SIGH-SAD) at 5 Weeks — 24.75; 12.88 SIGH-SAD score — p=.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Light therapy (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Michigan
Primary completion
Dec 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline Score of the Hamilton Depression Rating Scale-Seasonal Affective Version (SIGH-SAD) at 5 Weeks		 24.75; 12.88 .001 sig
PRIMARY
Change From Baseline Score of the Edinburgh Postnatal Depression Scale (EPDS) at 5 Weeks		 12.75; 7.75 .019 sig
PRIMARY
Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 5 Weeks		 -6 .502

Summary

The proposed study aims to establish the feasibility of light therapy for postpartum depression delivered via Re-Timer, demonstrate its preliminary efficacy, and illuminate relationships between circadian shifts and mood changes using a novel, home-based circadian biomarker assessment paradigm (salivary dim light melatonin onset; DLMO).

Eligibility Criteria

Inclusion Criteria

  • Within 6 months postpartum
  • Meet DSM-V diagnostic criteria for MDD
  • Score ≥ 20 on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder version (SIGH-SAD).

Exclusion Criteria

  • current diagnosis of bipolar disorder, posttraumatic stress disorder, schizophrenia or psychosis, dissociative disorders, eating disorder, obsessive-compulsive disorder, somatic symptom and related disorders, substance use disorder, panic disorder, agoraphobia per DSM-V
  • past history of mania/hypomania,
  • chronic medical conditions associated with depression (e.g., thyroid conditions)
  • ocular or retinal pathology
  • history of seizures or epilepsy
  • color blindness
  • Lupus
  • currently taking an antibiotic, medication that contains hydrochlorothiazide, or isotretinoin (Accutane).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02769858). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search